Literature DB >> 33425530

Acute Encephalopathic Presentation of 3-Methylglutaconic Aciduria Type I With a Novel Mutation in AUH Gene.

Sai Chandar Dudipala1,2, Prashanthi M2, Krishna Chaithanya B3, Laxman Kumar Chenalla2.   

Abstract

3-Methylglutaconic aciduria type I (3-MGA I) is a rare inherited disorder of the leucine metabolism pathway due to mutations in the AUH gene for 3-methylglutaconyl-CoA hydratase enzyme and enzyme deficiency. It has a variable phenotypic presentation from infancy to adulthood. Here, we report a three-year-old female patient with normal development presented with acute encephalopathy and status dystonicus. Neuroimaging was normal. Urine organic acid analysis showed high levels of 3-methylglutaconic acid, 3-hydroxyisovaleric acid. Next-generation sequencing revealed a novel homozygous mutation of variant c.505+1G>C (5' splice site) in intron 4 of the AUH gene that was compatible with the diagnosis of 3-MGA I. The child was asymptomatic on follow-up with a low leucine diet. Clinicians should suspect rare inherited metabolic disorders in acute onset unexplainable neurological symptoms and evaluate with urine organic acid analysis.
Copyright © 2020, Dudipala et al.

Entities:  

Keywords:  3-methylglutaconyl-coa hydratase; auh gene; low leucine diet

Year:  2020        PMID: 33425530      PMCID: PMC7785470          DOI: 10.7759/cureus.11951

Source DB:  PubMed          Journal:  Cureus        ISSN: 2168-8184


  2 in total

Review 1.  3-Methylglutaconic Aciduria Type I Due to AUH Defect: The Case Report of a Diagnostic Odyssey and a Review of the Literature.

Authors:  Francesca Nardecchia; Anna Caciotti; Teresa Giovanniello; Sabrina De Leo; Lorenzo Ferri; Serena Galosi; Silvia Santagata; Barbara Torres; Laura Bernardini; Claudia Carducci; Amelia Morrone; Vincenzo Leuzzi
Journal:  Int J Mol Sci       Date:  2022-04-16       Impact factor: 6.208

2.  An adult patient with 3-methylglutaconic aciduria type 1 and movement disorders.

Authors:  M Mainardi; L Lerjefors; G Bonato; C Bertolin; L Salviati; M Carecchio
Journal:  J Neurol       Date:  2022-02-03       Impact factor: 4.849

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.